Airway management

GlideScope versus C-MAC D-blade videolaryngoscope for double-lumen tube intubation in patients with anticipated difficult airways: A multi-center, prospective, randomized, controlled trial

J Clin AnesthPublished Randomised controlled trial

Authors' conclusion

In patients with difficult airways, the GlideScope and C-MAC D-blade provided a similar success rate on the first DLT intubation attempt; however, the C-MAC D-blade offers a better glottic view, easier and faster intubation, and lower incidence of sore throat.

Study context

Population
Adults with anticipated difficult airways undergoing elective thoracic surgery, 3 tertiary hospitals
Participants
348 adults
Comparison
GlideScope vs C-MAC D-blade videolaryngoscope for double-lumen tube (DLT) intubation
Primary endpoint
First-pass success rate of DLT intubation
Methodological detailsmulticentre, prospective, Three tertiary hospitals, 5 December 2020 to 4 November 2021
  • Multicentre
  • Prospective
  • Three tertiary hospitals, 5 December 2020 to 4 November 2021

Primary result

As reported in the abstract

P = 0.323

Secondary outcomes

Duration of DLT intubation · shorter with C-MAC D-blade

P < 0.001

Events

OutcomeGlideScopeC-MAC D-bladeP value
Cormack-Lehane gradeLower with C-MAC D-bladeP < 0.001
External laryngeal pressure4815P < 0.001
NRS difficulty of insertion into oral cavity, delivery to glottis, intubation into main bronchusSignificantly lower with C-MAC D-bladeP < 0.001
Fiberoptic intubation after 3 failed videolaryngoscope attempts22

Safety

Events

OutcomeGlideScopeC-MAC D-bladeP value
Postprocedure sore throat268P < 0.001

Original publication

GlideScope versus C-MAC D-blade videolaryngoscope for double-lumen tube intubation in patients with anticipated difficult airways: A multi-center, prospective, randomized, controlled trial. J Clin Anesth. Published 4 October 2023. doi:10.1016/j.jclinane.2023.111274

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.